Chris Sampson’s journal round-up for 7th May 2018

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Building an international health economics teaching network. Health Economics [PubMedPublished 2nd May 2018

The teaching on my health economics MSc (at Sheffield) was very effective. Experts from our subdiscipline equipped me with the skills that I went on to use on a daily basis in my first job, and to this day. But not everyone gets the same opportunity. And there were only 8 people on my course. Part of the background to the new movement described in this editorial is the observation that demand for health economists outstrips supply. Great for us jobbing health economists, but suboptimal for society. The shortfall has given rise to people teaching health economics (or rather, economic evaluation methods) without any real training in economics. The main purpose of this editorial is to call on health economists (that’s me and you) to pull our weight and contribute to a collective effort to share, improve, and ultimately deliver high-quality teaching resources. The Health Economics education website, which is now being adopted by iHEA, should be the starting point. And there’s now a Teaching Health Economics Special Interest Group. So chip in! This paper got me thinking about how the blog could play its part in contributing to the infrastructure of health economics teaching, so expect to see some developments on that front.

Including future consumption and production in economic evaluation of interventions that save life-years: commentary. PharmacoEconomics – Open [PubMed] Published 30th April 2018

When people live longer, they spend their extra life-years consuming and producing. How much consuming and producing they do affects social welfare. The authors of this commentary are very clear about the point they wish to make, so I’ll just quote them: “All else equal, a given number of quality-adjusted life-years (QALYs) from life prolongation will normally be more costly from a societal perspective than the same number of QALYs from programmes that improve quality of life”. This is because (in high-income countries) most people whose life can be extended are elderly, so they’re not very productive. They’re likely to create a net cost for society (given how we measure value). Asserting that the cost is ‘worth it’ at any level, or simply ignoring the matter, isn’t really good enough because providing life extension will be at the expense of some life-improving treatments which may – were these costs taken into account – improve social welfare. The authors’ estimates suggest that the societal cost of life-extension is far greater than current methods admit. Consumption costs and production gains should be estimated and should be given some weight in decision-making. The question is not whether we should measure consumption costs and production gains – clearly, we should. The question is what weight they ought to be given in decision-making.

Methods for the economic evaluation of changes to the organisation and delivery of health services: principal challenges and recommendations. Health Economics, Policy and Law [PubMedPublished 20th April 2018

The late, great, Alan Maynard liked to speak about redisorganisations in the NHS: large-scale changes to the way services are organised and delivered, usually without a supporting evidence base. This problem extends to smaller-scale service delivery interventions. There’s no requirement for policy-makers to demonstrate that changes will be cost-effective. This paper explains why applying methods of health technology assessment to service interventions can be tricky. The causal chain of effects may be less clear when interventions are applied at the organisational level rather than individual level, and the results will be heavily dependent on the present context. The author outlines five challenges in conducting economic evaluations for service interventions: i) conducting ex-ante evaluations, ii) evaluating impact in terms of QALYs, iii) assessing costs and opportunity costs, iv) accounting for spillover effects, and v) generalisability. Those identified as most limiting right now are the challenges associated with estimating costs and QALYs. Cost data aren’t likely to be readily available at the individual level and may not be easily identifiable and divisible. So top-down programme-level costs may be all we have to work with, and they may lack precision. QALYs may be ‘attached’ to service interventions by applying a tariff to individual patients or by supplementing the analysis with simulation modelling. But more methodological development is still needed. And until we figure it out, health spending is likely to suffer from allocative inefficiencies.

Vog: using volcanic eruptions to estimate the health costs of particulates. The Economic Journal [RePEc] Published 12th April 2018

As sources of random shocks to a system go, a volcanic eruption is pretty good. A major policy concern around the world – particularly in big cities – is the impact of pollution. But the short-term impact of particulate pollution is difficult to identify because there is high correlation amongst pollutants. In this study, the authors use the eruption activity of Kīlauea on the island of Hawaiʻi as a source of variation in particulate pollution. Vog – volcanic smog – includes sulphur dioxide and is similar to particulate pollution in cities, but the fact that Hawaiʻi does not have the same levels of industrial pollutants means that the authors can more cleanly identify the impact on health outcomes. In 2008 there was a big increase in Kīlauea’s emissions when a new vent opened, and the level of emissions fluctuates daily, so there’s plenty of variation to play with. The authors have two main sources of data: emergency admissions (and their associated charges) and air quality data. A parsimonious OLS model is used to estimate the impact of air quality on the total number of admissions for a given day in a given region, with fixed effects for region and date. An instrumental variable approach is also used, which looks at air quality on a neighbouring island and uses wind direction to specify the instrumental variable. The authors find that pulmonary-related emergency admissions increased with pollution levels. Looking at the instrumental variable analysis, a one standard deviation increase in particulate pollution results in 23-36% more pulmonary-related emergency visits (depending on which measure of particulate pollution is being used). Importantly, there’s no impact on fractures, which we wouldn’t expect to be influenced by the particulate pollution. The impact is greatest for babies and young children. And it’s worth bearing in mind that avoidance behaviours – e.g. people staying indoors on ‘voggy’ days – are likely to reduce the impact of the pollution. Despite the apparent lack of similarity between Hawaiʻi and – for example – London, this study provides strong evidence that policy-makers should consider the potential savings to the health service when tackling particulate pollution.


Chris Sampson’s journal round-up for 19th March 2018

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund. BMJ Open [PubMed] Published 8th March 2018

As well as the cost-effectiveness of health care, economists are increasingly concerned with the cost-effectiveness of health research. This makes sense, given that both are usually publicly funded and so spending on one (in principle) limits spending on the other. NICE exists in part to prevent waste in the provision of health care – seeking to maximise benefit. In this paper, the authors (all current or ex-employees of NICE) consider the extent to which NICE processes are also be used to prevent waste in health research. The study focuses on the processes underlying NICE guideline development and HTA, and the work by NICE’s Science Policy and Research (SP&R) programme. Through systematic review and (sometimes) economic modelling, NICE guidelines identify research needs, and NICE works with the National Institute for Health Research to get their recommended research commissioned, with some research fast-tracked as ‘NICE Key Priorities’. Sometimes, it’s also necessary to prioritise research into methodological development, and NICE have conducted reviews to address this, with the Internal Research Advisory Group established to ensure that methodological research is commissioned. The paper also highlights the roles of other groups such as the Decision Support Unit, Technical Support Unit and External Assessment Centres. This paper is useful for two reasons. First, it gives a clear and concise explanation of NICE’s processes with respect to research prioritisation, and maps out the working groups involved. This will provide researchers with an understanding of how their work fits into this process. Second, the paper highlights NICE’s current research priorities and provides insight into how these develop. This could be helpful to researchers looking to develop new ideas and proposals that will align with NICE’s priorities.

The impact of the minimum wage on health. International Journal of Health Economics and Management [PubMed] Published 7th March 2018

The minimum wage is one of those policies that is so far-reaching, and with such ambiguous implications for different people, that research into its impact can deliver dramatically different conclusions. This study uses American data and takes advantage of the fact that different states have different minimum wage levels. The authors try to look at a broad range of mechanisms by which minimum wage can affect health. A major focus is on risky health behaviours. The study uses data from the Behavioral Risk Factor Surveillance System, which includes around 300,000 respondents per year across all states. Relevant variables from these data characterise smoking, drinking, and fruit and vegetable consumption, as well as obesity. There are also indicators of health care access and self-reported health. The authors cut their sample to include 21-64-year-olds with no more than a high school degree. Difference-in-differences are estimated by OLS according to individual states’ minimum wage changes. As is often the case for minimum wage studies, the authors find several non-significant effects: smoking and drinking don’t seem to be affected. Similarly, there isn’t much of an impact on health care access. There seems to be a small positive impact of minimum wage on the likelihood of being obese, but no impact on BMI. I’m not sure how to interpret that, but there is also evidence that a minimum wage increase leads to a reduction in fruit and vegetable consumption, which adds credence to the obesity finding. The results also demonstrate that a minimum wage increase can reduce the number of days that people report to be in poor health. But generally – on aggregate – there isn’t much going on at all. So the authors look at subgroups. Smoking is found to increase (and BMI decrease) with minimum wage for younger non-married white males. Obesity is more likely to be increased by minimum wage hikes for people who are white or married, and especially for those in older age groups. Women seem to benefit from fewer days with mental health problems. The main concerns identified in this paper are that minimum wage increases could increase smoking in young men and could reduce fruit and veg consumption. But I don’t think we should overstate it. There’s a lot going on in the data, and though the authors do a good job of trying to identify the effects, other explanations can’t be excluded. Minimum wage increases probably don’t have a major direct impact on health behaviours – positive or negative – but policymakers should take note of the potential value in providing public health interventions to those groups of people who are likely to be affected by the minimum wage.

Aligning policy objectives and payment design in palliative care. BMC Palliative Care [PubMed] Published 7th March 2018

Health care at the end of life – including palliative care – presents challenges in evaluation. The focus is on improving patients’ quality of life, but it’s also about satisfying preferences for processes of care, the experiences of carers, and providing a ‘good death’. And partly because these things can be difficult to measure, it can be difficult to design payment mechanisms to achieve desirable outcomes. Perhaps that’s why there is no current standard approach to funding for palliative care, with a lot of variation between countries, despite the common aspiration for universality. This paper tackles the question of payment design with a discussion of the literature. Traditionally, palliative care has been funded by block payments, per diems, or fee-for-service. The author starts with the acknowledgement that there are two challenges to ensuring value for money in palliative care: moral hazard and adverse selection. Providers may over-supply because of fee-for-service funding arrangements, or they may ‘cream-skim’ patients. Adverse selection may arise in an insurance-based system, with demand from high-risk people causing the market to fail. These problems could potentially be solved by capitation-based payments and risk adjustment. The market could also be warped by blunt eligibility restrictions and funding caps. Another difficulty is the challenge of achieving allocative efficiency between home-based and hospital-based services, made plain by the fact that, in many countries, a majority of people die in hospital despite a preference for dying at home. The author describes developments (particularly in Australia) in activity-based funding for palliative care. An interesting proposal – though not discussed in enough detail – is that payments could be made for each death (per mortems?). Capitation-based payment models are considered and the extent to which pay-for-performance could be incorporated is also discussed – the latter being potentially important in achieving those process outcomes that matter so much in palliative care. Yet another challenge is the question of when palliative care should come into play, because, in some cases, it’s a matter of sooner being better, because the provision of palliative care can give rise to less costly and more preferred treatment pathways. Thus, palliative care funding models will have implications for the funding of acute care. Throughout, the paper includes examples from different countries, along with a wealth of references to dig into. Helpfully, the author explicitly states in a table the models that different settings ought to adopt, given their prevailing model. As our population ages and the purse strings tighten, this is a discussion we can expect to be having more and more.



Chris Sampson’s journal round-up for 4th December 2017

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Funding breakthrough therapies: a systematic review and recommendation. Health Policy Published 2nd December 2017

One of the (numerous) financial pressures on health care funders in the West is the introduction of innovative (and generally very expensive) new therapies. Some of these can be considered curative, which isn’t necessarily the best way for manufacturers to create a steady income. New funding arrangements have been proposed to facilitate patient access while maintaining financial sustainability. This article focuses on a specific group of innovative therapies known as ‘Advanced Therapy Medicinal Products’ (ATMPs), which includes gene therapies. The authors conducted a systematic review of papers proposing funding models and considered their appropriateness for ATMPs. There were 48 papers included in the review that proposed payment mechanisms for high-cost therapies. Three top-level groups were identified: i) financial agreements, ii) performance-based agreements, and iii) healthcoin (a tradable currency representing the value of outcomes). The different mechanisms are compared in terms of their feasibility, acceptability, burden, ‘financial attractiveness’ and their appeal to payers and manufacturers. Annuity payments are identified as relatively attractive compared to other options, but each mechanism is summarily shown to be imperfect in the ATMP context. So, instead, the authors propose an ATMP-specific fund. For UK readers, this will likely smell a bit too much like the disastrous Cancer Drugs Fund. It isn’t clear why such a programme would be superior to annuity payments or more inventive mechanisms, or even whether it would be theoretically sound. Thus, the proposal is not convincing.

Supply-side effects from public insurance expansions: evidence from physician labor markets. Health Economics [PubMed] Published 1st December 2017

Crazy though American health care may be, its inconsistency in coverage can make for good research fodder. The Child Health Insurance Program (CHIP) was set up in 1997 and then, when the initial money ran out 10 years later, the program was (eventually) expanded. In this study, the authors use the changes in CHIP to examine the impact of expanded public coverage on provider behaviour, namely; subspecialty training (which could become more attractive with a well-insured customer base), practice setting and prevailing wage offers. The data for the study relate to the physician labour market for New York state for 2002-2013, as collected in the Graduate Medical Education survey. A simple difference-in-differences analysis is conducted with reference to the 2009 CHIP expansion, controlling for physician demographics. Paediatricians are the treatment group and the control group is adult physician generalists (mostly internal medicine). 2009 seems to be associated with a step-change in the proportion of paediatricians choosing to subspecialise – an increased probability of about 8 percentage points. There is also an upward shift in the proportion of paediatricians entering private practice, with some (weak) evidence that there is an increased preference for rural areas. These changes don’t seem to be driven by relative wage increases, with no major change in trends. So it seems that the expanded coverage did have important supply-side effects. But the waters are muddy here. In particular, we have the Great Recession and Obamacare as possible alternative explanations. Though it’s difficult to come up with good reasons for why these might better explain the observed changes.

Reflections on the NICE decision to reject patient production losses. International Journal of Technology Assessment in Health Care [PubMedPublished 20th November 2017

When people conduct economic evaluations ‘from a societal perspective’, this often just means a health service perspective with productivity losses added. NICE explicitly exclude the inclusion of these production losses in health technology appraisals. This paper reviews the issues at play, focussing on the normative question of why they should (or should not) be included. Findings from a literature review are summarised with reference to the ethical, theoretical and policy questions. Unethical discrimination potentially occurs if people are denied health care on the basis of non-health-related characteristics, such as the ability to work. All else equal, should health care for men be prioritised over health care for women because men have higher wages? Are the unemployed less of a priority because they’re unemployed? The only basis on which to defend the efficiency of an approach that includes productivity losses seems to be a neoclassical welfarist one, which is hardly tenable in the context of health care. If we adopt the extra-welfarist understanding of opportunity cost as foregone health then there is really no place for production losses. The authors also argue that including production losses may be at odds with policy objectives, at least in the context of the NHS in the UK. Health systems based on privately-funded care or social insurance may have different priorities. The article concludes that taking account of production losses is at odds with the goal of health maximisation and therefore the purpose of the NHS in the UK. Personally, I think priority setting in health care should take a narrow health perspective. So I agree with the authors that production losses shouldn’t be included. I’m not sure this article will convince those who disagree, but it’s good to have a reference to vindicate NICE’s position.